ABC: Adjuvant Breast Cancer trial
|Dates:||2004 - 2006|
|Funding:||Medical Research Council|
|Collaborators:||Institute of Cancer, Royal Marsden Hospital|
The aim of the United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Adjuvant Breast Cancer (ABC) Trial was to evaluate whether adding chemotherapy and/or ovarian suppression to tamoxifen is effective and cost-effective in the treatment of women with early breast cancer.
All women recruited to the trial received tamoxifen. For pre/peri-menopausal women, there were three randomisation options:
- chemotherapy versus no chemotherapy;
- ovarian suppression versus no ovarian suppression;
- chemotherapy versus no chemotherapy and ovarian suppression versus no ovarian suppression.
Post-menopausal women were randomised to chemotherapy or no chemotherapy.
The trial's primary outcome measures were overall and relapse free survival and were examined for two principal comparisons: ± ovarian suppression in pre/peri-menopausal women, and ± chemotherapy for all women. The economic evaluation also carried out for these comparisons uses patient-specific and published resource use data relating to adjuvant therapies, treatments for any therapy induced toxicities and recurrences, and numbers of visits made to GPs, outpatient clinics and other health care professionals. Patient outcome is measured as both survival and quality adjusted survival (or QALYs), calculated by weighting survival by health state utilities derived by administering the EuroQol EQ-5D questionnaire to a sub-group of patients in the trial.
The economic evaluation conducted alongside this trial has now been completed.
Campbell, HE, Taylor, MA, Harris, AL, and Gray, AM (2009). An investigation into the performance of the Adjuvant! Online prognostic programme in early breast cancer for a cohort of patients in the United Kingdom. Br J Cancer, 101(7):1074-84.